This antibody is predicted to react with human and rat based on sequence homology.
MET is a tyrosine kinase receptor for the hepatocyte growth factor. It is linked to functions such as cell proliferation, scattering, morphogenesis, and survival. Ligand binding at the cell surface induces autophosphorylation of MET that provides docking sites for downstream signaling molecules. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: cMet; EC 220.127.116.11; Hepatocyte growth factor receptor; HGF receptor; HGF-SF receptor; HGF/SF receptor; met proto-oncogene tyrosine kinase; oncogene MET; Proto-oncogene c-Met; sc MET; Scatter factor receptor; SF receptor; soluble c met; Tyrosine-protein kinase Met
Gene Aliases: AI838057; AUTS9; c-Met; DFNB97; HGF; HGFR; MET; Par4; RCCP2
UniProt ID: (Human) P08581
Molecular Function: transmembrane signal receptor